Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
TI2-M5253 | Mouse | Mouse TIE2 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
TI2-C5253 | Cynomolgus | Cynomolgus TIE2 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
TI2-H5255 | Human | Human TIE2 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Biotinylated Human Angiopoietin-2, His,Avitag (Cat. No. AN2-H82E7) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human TIE2, Fc Tag (Cat. No. TI2-H5255) with a linear range of 0.6-10 ng/mL (QC tested).
The purity of Mouse TIE2, Fc Tag (Cat. No. TI2-M5253) is more than 90% and the molecular weight of this protein is around 235-285kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | Japan | Carcinoma, Renal Cell | Takeda | 2012-11-29 | Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Pain; Esophageal Neoplasms; Glioblastoma; Kidney Diseases; Prostatic Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Thyroid Neoplasms; Carcinoma, Neuroendocrine; Lymphoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Ponatinib Hydrochloride | AP-24534; INCB-84344; AP24534 HCl; AP24534-HCL; AP24534 hydrochloride | Approved | Ariad | Iclusig | Japan | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Otsuka Holdings Co Ltd | 2012-12-14 | Leukemia; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Solid tumours; Hematologic Neoplasms; Blast Crisis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Philadelphia Chromosome; Leukemia, Myeloid, Chronic-Phase; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute; Lymphoma; Leukemia, Biphenotypic, Acute | Details |
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer Ag | Resihance, Stivarga | Mainland China | Gastrointestinal Stromal Tumors | Bayer Pharma Ag | 2012-09-27 | Solid tumours; Carcinoma, Renal Cell; Rectal Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Razuprotafib | AKB-9778 | Phase 2 Clinical | Akebia Therapeutics | Coronavirus Disease 2019 (COVID-19); Glaucoma, Open-Angle; Respiratory Distress Syndrome, Adult; Ocular Hypertension; Diabetic macular oedema; Retinal Vein Occlusion; Diabetic Retinopathy | Details |
CEP-11981 | ESK-981; CEP-11981; SSR-106462; BOL-303213X | Phase 2 Clinical | Sanofi | Prostatic Neoplasms | Details |
Altiratinib | DP-5164; DCC-2701; DCC-22701; T-678746713 | Phase 1 Clinical | Deciphera | Solid tumours; Neoplasms | Details |
Rebastinib Tosylate | DP-1919; DCC-2036; DP-1919.TO | Phase 2 Clinical | Deciphera | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Solid tumours; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
AXT-107 | AXT-107 | Phase 2 Clinical | AsclepiX Therapeutics Inc | Diabetic macular oedema; Macular Degeneration | Details |
Sitravatinib | MG-516; MG-91516; MGCD-516; IND-155305 | Phase 3 Clinical | Mirati Therapeutics | Solid tumours; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Hepatic Insufficiency; Ureteral Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular | Details |
QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
This web search service is supported by Google Inc.